Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 7/20 | 0.35 |
| ▸ | HAT1 | O14929 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | ATP4A | P20648 | 3/20 | 0.34 |
| ▸ | ATP4B | P51164 | 3/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 2/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988787 | 0.91 | GHSR (0.67) | GHSRHTR6HTR1A | |
| SCHEMBL10121669 | 0.86 | GHSR (0.61) | GHSRPLA2G4A | |
| SCHEMBL1993722 | 0.84 | GHSR (0.81) | GHSRHTR1A | |
| SCHEMBL1989289 | 0.84 | GHSR (0.66) | GHSR | |
| SCHEMBL1992391 | 0.84 | GHSR (0.72) | GHSR | |
| SCHEMBL1986948 | 0.81 | GHSR (0.71) | GHSRHTR1A | |
| SCHEMBL1989790 | 0.79 | GHSR (0.72) | GHSRHTR1A | |
| SCHEMBL1988495 | 0.79 | GHSR (0.62) | GHSRHTR1A | |
| SCHEMBL1994659 | 0.79 | GHSR (0.58) | GHSRHTR6HTR1A | |
| SCHEMBL10122112 | 0.78 | GHSR (0.64) | GHSRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885HTR6 764/4885HAT1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.